Published in Biomark Med on February 01, 2013
Cancer and orofacial pain. Med Oral Patol Oral Cir Bucal (2016) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42
Cell signaling by receptor tyrosine kinases. Cell (2000) 18.16
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Angiogenesis in health and disease. Nat Med (2003) 14.02
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med (2000) 13.24
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2004) 10.55
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Specific carcinoembryonic antigens of the human digestive system. J Exp Med (1965) 9.96
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med (2012) 9.17
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med (1987) 6.41
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2001) 5.17
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol (2006) 5.02
AN " ACID " PHOSPHATASE OCCURRING IN THE SERUM OF PATIENTS WITH METASTASIZING CARCINOMA OF THE PROSTATE GLAND. J Clin Invest (1938) 5.00
The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol (1999) 4.65
Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev (2000) 4.10
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood (2011) 3.82
Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci (2009) 3.59
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist (2009) 3.18
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood (2012) 2.97
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood (2009) 2.79
Multiple developmental roles of VEGF suggested by a LacZ-tagged allele. Dev Biol (1999) 2.59
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther (2009) 2.52
Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst (1995) 2.47
NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res (2006) 2.44
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res (2000) 2.23
Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. Nat Rev Clin Oncol (2011) 2.15
A lymphocyte-stimulating factor produced in vitro. Nature (1965) 2.12
Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst (2012) 2.09
Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med (2012) 2.04
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res (2001) 2.01
Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol (1998) 1.90
Immune suppression in the tumor microenvironment. J Immunother (2006) 1.90
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90
Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol (2010) 1.86
Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. Proc Natl Acad Sci U S A (1980) 1.85
Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. J Exp Med (1995) 1.78
Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci U S A (1996) 1.77
Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer (1998) 1.65
Development of the polymer micelle carrier system for doxorubicin. J Control Release (2001) 1.64
Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res (2011) 1.53
Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res (2000) 1.52
Molecular targets for breast cancer therapy and prevention. Nat Med (2001) 1.50
Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst (1988) 1.49
A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol (2010) 1.45
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol (2006) 1.42
Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest (2007) 1.40
Development of Herceptin resistance in breast cancer cells. Cytometry A (2004) 1.39
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother (2010) 1.38
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol (2010) 1.38
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther (2011) 1.36
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res (2007) 1.36
IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res (2011) 1.33
Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol (2005) 1.32
Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res (2012) 1.32
Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells. Science (1970) 1.29
The paracrine hormone hypothesis of colorectal cancer. Clin Pharmacol Ther (2007) 1.26
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother (2008) 1.25
Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA (2009) 1.21
Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann Intern Med (1999) 1.21
Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy. Oncoimmunology (2012) 1.16
Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther (2010) 1.16
Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res (1999) 1.15
Escherichia coli heat-stable toxin receptors in human colonic tumors. Gastroenterology (1994) 1.14
Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res (2002) 1.13
Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst (2008) 1.12
Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther (2010) 1.10
Expression of guanylin is downregulated in mouse and human intestinal adenomas. Biochem Biophys Res Commun (2000) 1.10
Guanylin and uroguanylin induce natriuresis in mice lacking guanylyl cyclase-C receptor. Kidney Int (2004) 1.09
A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med (2012) 1.07
Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev Mol Diagn (2005) 1.07
T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood (2011) 1.07
Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models. Blood (2012) 1.06
Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J Immunother (1998) 1.06
Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer. Dis Colon Rectum (1998) 1.05
Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary. Expert Opin Pharmacother (2006) 1.04
Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother (2002) 2.68
Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology (2007) 1.63
Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer. Clin Cancer Res (2011) 1.59
First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol (2003) 1.55
Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy. Eur J Immunol (2014) 1.49
A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin Cancer Res (2006) 1.42
Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol (2005) 1.32
The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clin Cancer Res (2005) 1.31
The transcription factor encyclopedia. Genome Biol (2012) 1.28
Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am J Pathol (2007) 1.28
A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. J Clin Invest (2011) 1.27
Translating MicroRNA discovery into clinical biomarkers in cancer. JAMA (2007) 1.20
Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol (2003) 1.15
Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst (2008) 1.12
Selection of optimal reference genes for normalization in quantitative RT-PCR. BMC Bioinformatics (2010) 1.11
Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol (2006) 1.09
Bile acids induce ectopic expression of intestinal guanylyl cyclase C Through nuclear factor-kappaB and Cdx2 in human esophageal cells. Gastroenterology (2006) 1.09
Functional macroautophagy induction by influenza A virus without a contribution to major histocompatibility complex class II-restricted presentation. J Virol (2011) 1.07
Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev Mol Diagn (2005) 1.07
Indinavir and rifabutin drug interactions in healthy volunteers. J Clin Pharmacol (2004) 1.05
Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res (2009) 1.01
Genetics and genomics for the prevention and treatment of cardiovascular disease: update: a scientific statement from the American Heart Association. Circulation (2013) 1.01
In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C--specific ligand. J Nucl Med (2002) 0.97
Applications of nanoparticles to diagnostics and therapeutics in colorectal cancer. Trends Biotechnol (2007) 0.96
Interruption of homologous desensitization in cyclic guanosine 3',5'-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins. Cancer Res (2005) 0.96
Mucosally restricted antigens as novel immunological targets for antitumor therapy. Biomark Med (2007) 0.95
Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer. Clin Cancer Res (2006) 0.94
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer. Discov Med (2014) 0.93
The adipose tissue production of adiponectin is increased in end-stage renal disease. Kidney Int (2013) 0.93
Taking a lesson from microbial diarrheagenesis in the management of chronic constipation. Gastroenterology (2010) 0.92
Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: a novel application in pediatric nanomedicine. Mol Pharm (2012) 0.91
Molecular staging individualizing cancer management. J Surg Oncol (2012) 0.90
Guanylyl cyclase C prevents colon cancer metastasis by regulating tumor epithelial cell matrix metalloproteinase-9. Cancer Res (2009) 0.90
Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother (2004) 0.89
The pharmacokinetics of taurolidine metabolites in healthy volunteers. J Clin Pharmacol (2007) 0.89
Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther (2003) 0.89
Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment. Cancer Immunol Res (2013) 0.88
Proliferative signaling by store-operated calcium channels opposes colon cancer cell cytostasis induced by bacterial enterotoxins. J Pharmacol Exp Ther (2005) 0.87
Phosphorylation of vasodilator-stimulated phosphoprotein Ser239 suppresses filopodia and invadopodia in colon cancer. Int J Cancer (2011) 0.87
Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target. Future Oncol (2009) 0.87
Colorectal cancer immunotherapy. Discov Med (2013) 0.87
Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer. Cancer Res (2013) 0.86
Molecular staging of node negative patients with colorectal cancer. J Cancer (2013) 0.86
Contrast-enhanced ultrasound imaging of sentinel lymph nodes after peritumoral administration of Sonazoid in a melanoma tumor animal model. J Ultrasound Med (2011) 0.86
The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharmacol (2004) 0.85
Nitric oxide activation of soluble guanylyl cyclase reveals high and low affinity sites that mediate allosteric inhibition by calcium. Biochemistry (2002) 0.85
GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome? Drug News Perspect (2009) 0.85
Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach. Cancer Epidemiol Biomarkers Prev (2002) 0.85
Obesity pharmacotherapy: what is next? Mol Aspects Med (2012) 0.84
Nitric oxide signaling: systems integration of oxygen balance in defense of cell integrity. Curr Opin Hematol (2004) 0.84
Soluble guanylate cyclase is allosterically inhibited by direct interaction with 2-substituted adenine nucleotides. Eur J Biochem (2002) 0.83
Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer. J Surg Oncol (2012) 0.83
Evidence-based Guidelines for Precision Risk Stratification-Based Screening (PRSBS) for Colorectal Cancer: Lessons learned from the US Armed Forces: Consensus and Future Directions. J Cancer (2013) 0.82
Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C. Cancer Immunol Immunother (2011) 0.82
Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas. Hum Pathol (2009) 0.82
Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes. Cancer (2011) 0.81
A comparative molecular field analysis (COMFA) of the structural determinants of heat-stable enterotoxins mediating activation of guanylyl cyclase C. J Med Chem (2002) 0.81
A conserved tissue-specific homeodomain-less isoform of MEIS1 is downregulated in colorectal cancer. PLoS One (2011) 0.81
Advances in cancer immunotherapy. Discov Med (2013) 0.81
Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells. Carcinogenesis (2008) 0.81
Bile acids initiate lineage-addicted gastroesophageal tumorigenesis by suppressing the EGF receptor-AKT axis. Clin Transl Sci (2009) 0.80
Clinical pharmacology at the core of translational science. Expert Rev Clin Pharmacol (2011) 0.80
Widening the path to personalized medicine. Clin Transl Sci (2011) 0.80
GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients. Expert Rev Mol Diagn (2009) 0.80
Pathological staging and therapy of oesophageal and gastric cancer. Expert Opin Pharmacother (2003) 0.80
Translational medicine: path to personalized and public health. Biomark Med (2010) 0.80
Guanylyl cyclase C as a biomarker in colorectal cancer. Biomark Med (2013) 0.79
Bacterial heat-stable enterotoxins: translation of pathogenic peptides into novel targeted diagnostics and therapeutics. Toxins (Basel) (2010) 0.79
Molecular staging estimates occult tumor burden in colorectal cancer. Adv Clin Chem (2010) 0.79
Where medicine, business, and public policy intersect. Biotechnol Healthc (2007) 0.79
GUCY2C: at the intersection of obesity and cancer. Trends Endocrinol Metab (2013) 0.79
Comparative Evaluation of Veriflow® Listeria monocytogenes to USDA and AOAC Culture Based Methods for the Detection of Listeria monocytogenes in Food. J AOAC Int (2015) 0.79
New advances in models and strategies for developing anti-obesity drugs. Expert Opin Drug Discov (2013) 0.79
GUCY2C-targeted cancer immunotherapy: past, present and future. Immunol Res (2011) 0.78
STa peptide analogs for probing guanylyl cyclase C. Biopolymers (2008) 0.78
H-ras inhibits RhoA/ROCK leading to a decrease in the basal tone in the internal anal sphincter. Gastroenterology (2007) 0.78
Sizing up pharmacotherapy for obesity. Clin Transl Sci (2010) 0.78
Cytokine adjuvanation of therapeutic anti-tumor immunity targeted to cancer mucosa antigens. Clin Transl Sci (2008) 0.78
Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis. Expert Rev Clin Pharmacol (2013) 0.78
Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis. Cancer Biol Ther (2010) 0.78
Derivation and fluidity of acutely induced dysfunctional CD8+ T cells. J Immunol (2008) 0.78
GUCY2C molecular staging personalizes colorectal cancer patient management. Biomark Med (2012) 0.78
Acquired and innate cardioprotection. J Appl Physiol (1985) (2007) 0.78
Chemiluminescence-based detection of gastrointestinal malignancies. Luminescence (2009) 0.77
Regulation of appetite to treat obesity. Expert Rev Clin Pharmacol (2011) 0.77
Reciprocal regulation and integration of signaling by intracellular calcium and cyclic GMP. Vitam Horm (2004) 0.77
Exisulind and guanylyl cyclase C induce distinct antineoplastic signaling mechanisms in human colon cancer cells. Mol Cancer Ther (2006) 0.77
The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity. J Clin Pharmacol (2004) 0.76
Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity. Expert Rev Endocrinol Metab (2010) 0.76
Effect of mibefradil on CYP3A4 in vivo. J Clin Pharmacol (2003) 0.76
Sex modulates intestinal transformation by the tumor-suppressor GCC. Clin Transl Sci (2008) 0.75
Functional and molecular characterization of beta-adrenoceptors in the internal anal sphincter. J Pharmacol Exp Ther (2003) 0.75